Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer

Recent availability of immune checkpoint inhibitors has facilitated research involving programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1). However, the incidence and clinical implication of PD-1 and PD-L1 expression in prostate cancer remain poorly understood. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Meenal, Yang, Zhiming, Miyamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756626/
https://www.ncbi.nlm.nih.gov/pubmed/31567999
http://dx.doi.org/10.1097/MD.0000000000017257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756626/
https://www.ncbi.nlm.nih.gov/pubmed/31567999
http://dx.doi.org/10.1097/MD.0000000000017257

Ejemplares similares